TY - JOUR
T1 - Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
AU - Klobuch, Sebastian
AU - Seijkens, Tom T. P.
AU - Schumacher, Ton N.
AU - Haanen, John B. A. G.
N1 - Publisher Copyright: © Springer Nature Limited 2024.
PY - 2024/3
Y1 - 2024/3
N2 - Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapy with BRAF and MEK inhibitors have revolutionized the treatment of melanoma over the past decade. Despite these breakthroughs, the 5-year survival rate of patients with advanced-stage melanoma is at most 50%, emphasizing the need for additional therapeutic strategies. Adoptive cell therapy with tumour-infiltrating lymphocytes (TILs) is a therapeutic modality that has, in the past few years, demonstrated long-term clinical benefit in phase II/III trials involving patients with advanced-stage melanoma, including those with disease progression on ICIs and/or BRAF/MEK inhibitors. In this Review, we summarize the current status of TIL therapies for patients with advanced-stage melanoma, including potential upcoming marketing authorization, the characteristics of TIL therapy products, as well as future strategies that are expected to increase the efficacy of this promising cellular immunotherapy.
AB - Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapy with BRAF and MEK inhibitors have revolutionized the treatment of melanoma over the past decade. Despite these breakthroughs, the 5-year survival rate of patients with advanced-stage melanoma is at most 50%, emphasizing the need for additional therapeutic strategies. Adoptive cell therapy with tumour-infiltrating lymphocytes (TILs) is a therapeutic modality that has, in the past few years, demonstrated long-term clinical benefit in phase II/III trials involving patients with advanced-stage melanoma, including those with disease progression on ICIs and/or BRAF/MEK inhibitors. In this Review, we summarize the current status of TIL therapies for patients with advanced-stage melanoma, including potential upcoming marketing authorization, the characteristics of TIL therapy products, as well as future strategies that are expected to increase the efficacy of this promising cellular immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85181660524&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41571-023-00848-w
DO - https://doi.org/10.1038/s41571-023-00848-w
M3 - Review article
C2 - 38191921
SN - 1759-4774
VL - 21
SP - 173
EP - 184
JO - Nature reviews. Clinical oncology
JF - Nature reviews. Clinical oncology
IS - 3
ER -